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Abstract
Background: Protein kinases play a central role in tumor progression, regulating fundamental processes such as
angiogenesis, proliferation and metastasis. Such enzymes are an increasingly important class of drug target with small
molecule kinase inhibitors being a major focus in drug development. However, balancing drug specificity and efficacy is
problematic with off-target effects and toxicity issues.
Methodology: We have utilized a rational in silico-based approach to demonstrate the design and study of a novel
compound that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent
kinase 1 (CDK1). This compound acts by simultaneously inhibiting pro-angiogenic signal transduction and cell cycle
progression in primary endothelial cells. JK-31 displays potent in vitro activity against recombinant VEGFR2 and CDK1/cyclin
B proteins comparable to previously characterized inhibitors. Dual inhibition of the vascular endothelial growth factor A
(VEGF-A)-mediated signaling response and CDK1-mediated mitotic entry elicits anti-angiogenic activity both in an
endothelial-fibroblast co-culture model and a murine ex vivo model of angiogenesis.
Conclusions: We deduce that JK-31 reduces the growth of both human endothelial cells and human breast cancer cells in
vitro. This novel synthetic molecule has broad implications for development of similar multi-kinase inhibitors with anti-
angiogenic and anti-cancer properties. In silico design is an attractive and innovative method to aid such drug discovery.
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Introduction
Vasculogenesis is the de novo formation of a vascular network
whereas angiogenesis is the sprouting of new blood vessels [1,2].
However, angiogenesis is subverted in pathophysiological condi-
tions such as tumor growth and metastasis [2]. Vascular
endothelial growth factor receptor 2 (VEGFR2) is a transmem-
brane receptor tyrosine kinase expressed by vascular endothelial
cells and is essential for both vasculogenesis and angiogenesis [3].
VEGFR2 is also expressed in other vascular cell types and neurons
but the functional significance is unclear [4,5]. Binding of vascular
endothelial growth factor A (VEGF-A) to VEGFR2 promotes
receptor dimerization and tyrosine autophosphorylation, leading
to activation of signaling molecules including phospholipase Cc1
(PLCc1), Akt and extracellular signal-regulated kinase (ERK1/2)
[3]. Functional outputs of the VEGF-A-VEGFR2 axis include
endothelial cell migration, enhanced cell survival and ultimately
morphogenesis of hollow tubular conduits [6,7]. In addition,
uncontrolled cell division is a classic hallmark of solid tumor
development and metastasis [8]. Cyclin-dependent kinase 1
(CDK1; cdc2) is a serine/threonine protein kinase required for
mitotic progression in human cells [9] and heterodimerization
with a regulatory cyclin subunit controls serine/threonine protein
kinase activity and targeting [10]. In particular, CDK1/cyclin B
activity regulates cell cycle progression from G2 to M phase and is
needed to complete mitosis [11,12].
The development of kinase inhibitors with increased target
specificity often comes at the cost of reduced efficacy, principally
due to redundancy in signaling pathways [13]. Thus the rational
design of so-called ‘selectively non-selective’ inhibitors that target a
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unique and distinct subset of kinases is emerging as an attractive
strategy for disease therapy [13–15]. To this end, we hypothesized
that a dual small molecule inhibitor that simultaneously targets the
VEGFR2 tyrosine kinase and CDK1 serine/threonine kinase
would perturb both new blood vessel growth and cell cycle
progression by targeting endothelial cells and cancer cells
simultaneously. In this study, we used a combination of cutting-
edge in silico modeling approaches and informed design to
synthesize a novel aminotriazole-based compound (termed JK-31),
which was predicted to bind to the active sites of both the
VEGFR2 and CDK1 protein kinases. Here we show that such
dual inhibition of VEGFR2 and CDK1 kinase activity perturbs
proliferation of breast cancer cells and is a potent anti-angiogenic
agent, both in vitro and in an ex vivo murine model.
Materials and Methods
Ethics statement
Mouse studies were carried out in accordance with institutional
and national regulatory procedures under an animal project
licence approved by the UK Home Office.
Chemicals
Chemicals were purchased from Sigma-Aldrich (Poole, UK),
Merck (Nottingham, UK) or VWR (Lutterworth, UK) unless
otherwise stated.
Cell culture, pharmacology and immunoblotting
Human primary endothelial cells were isolated, cultured and
validated for classical endothelial markers (Figure S1A-S1E) as
previously described [16,17]. All experiments were conducted at
,6 cell passages. For growth factor stimulation studies, cells were
serum-starved overnight in MCDB-131 (Invitrogen) containing
0.2% (w/v) bovine serum albumin (BSA), pre-treated with JK-31
for 30 min and stimulated as described in accompanying figure
legends. Recombinant human VEGF-A165 was a gift from
Genentech Inc. (San Francisco, CA, USA), recombinant human
basic fibroblast growth factor (bFGF) and epidermal growth factor
(EGF) were purchased from R&D Systems (Abingdon, UK), acidic
FGF (aFGF) was a gift from ImmunoTools (Friesoythe, Germany)
and insulin-like growth factor-1 (IGF-1) was a gift from Hema
Viswambharan (University of Leeds, UK). Human MCF-7 breast
cancer epithelial cells were from Cancer Research UK (London,
UK) and were cultured in Dulbecco’s modified eagle medium
(DMEM) containing 10% (v/v) fetal bovine serum (FBS).
Vatalanib was from Novartis AG (Basel, Switzerland), sunitinib
was from Enzo Lifesciences (Exeter, UK) and staurosporine was
provided by Reaction Biology Corp. (Malvern, USA). SDS-PAGE
electrophoresis and immunoblotting were carried out as previously
described [18]. Antibodies to cyclin A, cyclin B, cyclin D1 and
CDK1 were from BD Transduction Labs (Oxford, UK).
Antibodies to FGFR1 and PLCc1 were from Santa Cruz
Biotechnology (CA, USA). Also used were anti-VEGFR2 extra-
cellular domain antibody (R&D Systems), anti-a-tubulin antibody
(Sigma-Aldrich) and anti-b-actin antibody (AbCam, Cambridge,
UK). All other antibodies were from Cell Signalling Technologies
(Danvers, USA).
Chemical synthesis of JK-31
To a solution of N-cyano-S-methyl-N’phenylisothiourea (0.20 g,
1.04 mmol, 1.0 eq) in ethanol (10 ml), hydrazine hydrate (50 ml,
1.04 mmol, 1.0 eq) was added and heated to reflux until the starting
material was consumed. The solvent was evaporated in vacuo and
triturated with ether to leave N-phenyl-1H-1,2,4-triazole-3,5-
diamine (JK-31/INT), a colorless solid (0.16 g, 0.88 mmol, 85%).
To a solution of JK-31/INT (0.10 g, 0.57 mmol, 1.0 eq) in 5 ml
acetone at 0uC, pyridine (50 ml, 0.57 mmol, 1.0 eq) and 4- tert-
butyl-benzoyl chloride (100 ml, 0.57 mmol, 1.0 eq) was added. The
reaction mixture was stirred at room temperature for 4 h. The
solvent was removed under reduced pressure and the residue diluted
in water (10 ml). Solids were collected by filtration, washing with
water, and the purified by flash chromatography (95:5 CH2Cl2/
CH3OH) to afford (5-amino-3-(phenylamino)-1H-1,2,4-triazol-1-
yl)(4-(tert-butyl)phenyl)methanone (JK-31) as a colorless solid
(0.11 g, 0.31 mmol, 56%).
Nuclear magnetic resonance (NMR) spectroscopy
Proton nuclear magnetic resonance (1H NMR) spectra were
recorded at 500 MHz on a Bruker DRX500 instrument (Coven-
try, UK) as solutions in deuterated dimethyl sulfoxide (DMSO).
Chemical shifts are given in parts per million (ppm) with reference
to TMS in DMSO (2.5 ppm).13C NMR spectra were recorded at
125 MHz. Chemical shifts were quoted in ppm with reference to
the central peak of the deuterated DMSO at 40 ppm. Coupling
constants (J) were quoted in Hertz (Hz). Multiplicities were given
as singlet (s), doublet (d), triplet (t). Electrospray (ES) spectra were
recorded in house on a Bruker Daltonics micrOTOF spectrom-
eter. Thin layer chromatography (TLC) was performed using pre-
coated glass backed silica gel 60 F254 plates (Merck). The plates
were visualized using a ultraviolet (UV) lamp or by dipping in a
solution of permanganate. Silica gel 60 (particle size 37–70 mm;
Merck) was used for flash chromatography. HPLC analyses were
carried out on Dionex HPLC system using a Hyperprep HS C18
column with a gradient of acetonitrile and water (5–95%) with
0.1% TFA at a flow rate of 0.5 ml/min over a period of 5 min.
Spectra for JK-31: 1H NMR (500 MHz, DMSO d6): 9.27 (s,
1H), 8.16 (d, J 8.5 Hz, 2H), 7.82 (br s, 2H), 7.60 (d, J = 8.5 Hz,
2H), 7.54 (d, J 7.5 Hz, 2H), 7.23 (t, J 7.5 Hz, 2H), 6.85 (t,
J = 7.5 Hz, 1H), 1.33 (s, 9H); 13C NMR (125 MHz, DMSO d6):
166.3, 158.2, 157.4, 155.6, 140.9, 130.4, 129.7, 128.6, 124.7,
120.0, 116.6, 34.8, 30.8; Mass (ES+): C19H21N5O requires
335.1746, Found: 358.1638 (M+Na), HPLC (RT): 3.88 mins
(100%), CHN analysis (%): C19H21N5O requires C: 68.04, H:
6.31, N: 20.88 Found: C: 67.70, H: 6.20, N: 20.71.
Computational docking studies, informed molecular
design and homology modelling
As described above, JK-31 was conceived by simultaneous
analysis of the structure-activity relationship of known CDK1 and
VEGFR2 inhibitors. For example with reference to the CDK1
inhibitor JNJ-7706621, JK-31 contains the same aminotriazole
core, but the removal of a sulphonamide moiety and replacement
of a 2,6-difluorophenyl group with a 4-(tert-butyl)phenyl group
was predicted to aid binding to VEGFR2 whilst retaining CDK1-
inhibiting properties. Tert-butyl groups are observed in a number
of small molecule receptor tyrosine kinase inhibitors e.g.
PD173074 (Figure S2A). The binding pose of JK-31 was validated
against a number of known VEGFR2 and CDK1 inhibitors in
silico (Figure S3 and S4). The diaminothiazole compound shown
in Figure S2B and Figure S2C shares structural similarities with
JNJ-7706621.
Due to the high sequence homology between CDK1 and
CDK2 (66% homology in kinase domain), an available crystal
structure of CDK2 (PDB code: 3s2p) [19] was used to build a
homology model of CDK1. The sequence of CDK1 was imported
into the program Prime (Schro¨dinger Inc.) [20] and the model of
CDK1 was built using 3s2p as a template, which was further
subjected to protein preparation using Maestro and PrimeX
A Dual Specificity Cell Cycle and Angiogenesis Inhibitor
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(Schro¨dinger Inc.) (Figure 1B, Figure S2) [21]. Use of the
programs SPROUT (SimBioSys Inc.) [22,23] and Glide (Schro¨-
dinger Inc.) [24–26] for molecular modelling have been described
previously [27]. Briefly, JK-31 was docked into both the protein
kinase domains of either CDK1 and VEGFR2 (PDB code: 3cjg)
[28] using both programs. SPROUT identified a target region
where JK-31 would interact most strongly and was scored to give
an estimated pKi (Figure 1B, Table 1). Glide was also used to
predict the binding affinity of JK-31 (presented as a Glide score
where a lower score represents lower energy and thus greater
affinity; Table 1). Images from Glide software are used in this
publication (Figures 1B-1D, S2A and S2B). The binding mode of
JK-31 within the VEGFR2 and CDK1 kinase domains (with
respect to hydrogen bonding) were confirmed to be similar to
oneanother (Figures 1B–1D). A full description of the structure-
activity relationship of JK-31 and other compounds of the same
class is currently ongoing.
In vitro kinase profiling assay
JK-31, bohemine, vatalanib and staurosporine were screened
for inhibitory activity against the VEGFR2 and CDK1 kinases
using a 33P receptor tyrosine in vitro kinase HotSpotSM profiling
assay (Reaction Biology, Malvern, USA). Ten-point IC50 profiles
were generated using concentrations of JK-31 between 5 nM and
100 mM and a [c-33P]-ATP concentration of 10 mM.
Animal studies and ex vivo murine aortic ring
angiogenesis assay
Three male five-month old wild type C57Bl/6 mice were
humanely sacrificed followed by cervical dislocation. A thoraco-
abdominal incision was made and the heart and aorta excised and
stored in Hank’s balanced buffer. The aortas were cleaned by
removing connective tissue and adventitia from the exterior and
each aorta was cut into 18–24 rings. Ring explants were
embedded into growth-factor reduced Matrigel basement mem-
brane matrix (Beckton Dickinson) in a 24-well plate and incubated
for 45 min at 37uC to allow the Matrigel to set and the rings to
adhere. Rings were cultured ex vivo in MV2 mouse endothelial
cell growth medium (Promocell, Heidelberg, Germany) for six
days in the presence or absence of inhibitors, replacing the
medium every two days. Rings were photographed and the degree
of sprouting measured using Cell‘B imaging software (Olympus,
Tokyo, Japan). The mean of the three longest angiogenic sprouts
on each ring was measured.
Organotypic tubulogenesis assay
This assay was performed as previously described [18,27].
Primary human foreskin fibroblasts (pHFF) were a gift from
Gareth Howell (University of Leeds, UK) and were cultured
routinely in DMEM containing 10% (v/v) FBS up to passage 10.
In co-culture with HUVECs, the medium was replaced for
endothelial cell growth medium (Promocell, Heidelberg, Ger-
many).
Cell proliferation and scratch wound healing assays
Cell proliferation was measured using a bromodeoxyuridine
(BrdU) incorporation assays (Roche Diagnostics, Burgess Hill,
UK), performed in a 96-well plate with 2000 cells/well as
previously described [18,27]. For BrdU assays, cells were treated
with inhibitors for 16 h prior to assay. Scratch wound healing
assays were performed as previously described [18]. Briefly,
HUVECs were grown to confluence and starved for 3 h in serum-
free MCDB131 medium (Invitrogen, Amsterdam, Netherlands)
containing 0.2% (w/v) BSA. Cells were pre-treated with JK-31 for
1 h prior to making a vertical scratch wound through the cell
monolayer with a sterile 200 ml plastic pipette tip of ,0.9 mm tip
width. Wounded cell monolayers were washed once with PBS and
photographed. Cells were stimulated with 25 ng/ml VEGF-A for
16 h in the presence or absence of JK-31 and wounded cell
monolayers photographed once more. Wound widths were
measured using Image J software and % wound closure calculated
by ((width before – width after)/width before)6100.
MTS cell viability assay
2000 endothelial cells were seeded per well of a 96-well plate
and cultured in ECGM overnight. ECGM was then aspirated and
cells starved in MCDB131 +0.2% (w/v) BSA for 2 h. After 2 h,
media was changed for ECGM with or without DMSO, plus or
minus 100 nM, 1 mM, 10 mM or 50 mM JK-31 and cells
incubated for 48 h. Then, 10 ml of MTS reagent (CellTiter 96
AQueous Non-Radioactive Cell Proliferation Assay, Promega,
Madison, Wisconsin, USA) was added to each well after 44 h.
After further incubation for 4-6 h, we monitored the color change
caused by reduction of the yellow tetrazolium compound (MTS)
by metabolically active cells to brown formazan. Change in color
was monitored at 490 nm using a Tecan Sunrise multiwavelength
96-well plate reader (Tecan, Mannedorf, Switzerland).
Flow cytometry analysis of cell cycle progression
Endothelial (HUVECs) or human breast cancer (MCF-7) cells
were cultured to subconfluency (60–70% confluent) and treated
with either DMSO carrier alone or 200 nM nocodazole, 10 mM
bohemine, 100 nM sunitinib or JK-31 (1, 10 or 50 mM) in DMSO
for 48 h. Endothelial cells were detached from the tissue culture
plastic using TrypLE Express (Invitrogen, Amsterdam, Nether-
lands) and quenched with DMEM containing 10% (v/v) FCS and
cells transfered into 1.5 or 15 ml centrifuge tubes as appropriate.
Cells were pelleted at 140 g at 4uC for 5 min and supernatant
discarded. Cells were fixed in ice-cold 70% (v/v) ethanol added
dropwise and stored at 220uC prior to analysis. Immediately
before flow cytometry, cells were pelleted (140 g at 4uC for 5 min),
supernatant removed and cells washed twice in 500 ml PBS.
100 mg/ml ribonuclease and 50 mg/ml propidium iodide (Sigma-
Aldrich) was added to each sample and incubated for 2–3 h at
37uC. Cells were pelleted (140 g at 4uC for 5 min), supernatant
removed and cells washed in 500 ml PBS before being resuspended
in 500 ml PBS buffer containing 2.5 mM EDTA. Samples were
gated and run at a low flow rate (,1000 events s21) on a Fortessa
flow cytometer (Becton Dickinson, Oxford, UK) with multi-laser
and detection capabilities. The information from 10000 events was
collect and data was analyzed using ModFit software (Becton
Dickinson).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (La Jolla, CA, USA). For comparison between more
than two groups of data, one-way ANOVA with Tukey’s post hoc
test was used. Associated p values are noted in the figure legends.
Error bars denote 6 standard error of the mean (SEM).
Results
Design and in silico validation of JK-31: a dual VEGFR2/
CDK1 inhibitor
We performed a simultaneous analysis of the structure-activity
relationship of known CDK1 inhibitors e.g. AT7519 [29,30] and
JNJ-7706621 [31] and VEGFR2 inhibitors e.g. sunitinib,
A Dual Specificity Cell Cycle and Angiogenesis Inhibitor
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Figure 1. Dual targeting of VEGFR2 and CDK1. (A) Chemical structure of the aminotriazole-based compound JK-31. A full description of the
chemical synthesis can be found in the Materials and Methods section. (B) In silico molecular modeling of JK-31 (magenta structure) in the VEGFR2
and CDK1 kinase domains. A homology model of CDK1 was created using a structurally-related family member (CDK2 PDB code: 3s2p). The CDK1 and
VEGFR2 kinase domain sequences were aligned and overlapped. JK-31 was docked into the overlapped crystal structure using Glide program and
important amino acid residues identified. VEGFR2 crystal structure is shown in yellow and residues annotated in bold; CDK1 crystal structure is shown
in blue/grey and residues annotated in italics. (C) JK-31 was docked into a VEGFR2 crystal structure alone (PDB code: 3cjg) and predicted hydrogen
bond contacts identified. (D) JK-31 was docked into the CDK1 crystal structure homolog alone and predicted hydrogen bond contacts identified.
Dotted lines denote predicted hydrogen bond contacts. Green structures denote important kinase domain residues. Further details of these models
A Dual Specificity Cell Cycle and Angiogenesis Inhibitor
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pazopanib, vatalanib and PD173074 [18,27,28,32] to guide the
design of a compound based on an aminotriazole pharmacophore.
This molecule, JK-31, retains common structural features of both
VEGFR2 and CDK1 inhibitors (see Experimental Section for
further details of molecular design). Using the in silico molecular
modeling programs SPROUT and Glide, JK-31 was predicted to
bind with high affinity to the ATP-binding pocket of both the
VEGFR2 and CDK1 kinase domains respectively (Figure 1 and
Table 1).
We created a homology model of the CDK1 kinase domain
using information from the crystal structure of a related kinase,
CDK2 (PDB code: 3s2p) [19–21] (Figure S2B). The overall
homology of the VEGFR2 and CDK1 kinase domains was
relatively low (21.6%; Figure 1 and Figure S2A); however,
structural similarities exist within the ATP-binding region
(Figure 1B). In particular, using both programs SPROUT and
Glide [22–26], JK-31 was predicted to make three hydrogen bond
contacts with the VEGFR2 kinase domain (one with E917 and two
with C919) and with homologous residues in the CDK1 kinase
domain (one with E81 and two with L83) (Figures 1B–1D). The
program SPROUT predicted JK-31 to bind to both VEGFR2 and
CDK1 with a pKi of -7 or less (corresponding to a predicted
binding affinity in the nanomolar range, Table 1), with a slightly
better affinity predicted in the case of VEGFR2 (Table 1). Further
details of the docking studies are described in Figure S2.
Validation studies of the CDK1 homology model using previous-
ly-characterized CDK1 inhibitors AT7519 [29,30] and a diami-
nothizaole compound described by Schonbrunn and colleagues
[33] are shown in Figure S3. Validation of the binding pose of JK-
31 in the VEGFR2 kinase domain using previously-characterized
VEGFR2 inhibitors PD173074 [32], a derivative of pazopanib
and JK-P3 [27] is shown in Figure S4. JK-31 was synthesized from
commercially available reagents as described in the Materials and
Methods section.
JK-31 inhibits the intrinsic protein kinase activity of both
VEGFR2 and CDK1
To test the proposed ‘dual inhibitory’ potential of JK-31, we
examined the ability of this molecule to inhibit the intrinsic kinase
activities of either recombinant VEGFR2 or a recombinant
CDK1/cyclin B heterodimer in vitro using a [c-33P]-ATP kinase
assay with specific peptide substrates (Table 2; Figures 1E and F).
JK-31 showed dose-dependent inhibition of both protein kinases
but as predicted, displayed more potent inhibition of the
recombinant VEGFR2 receptor tyrosine kinase (Table 2; Figur-
es 1E and 1F). Intriguingly, JK-31 displayed greater inhibition of
CDK1 in comparison to a previously reported CDK1-specific
inhibitor, bohemine (Table 2 and Figure 1F) and showed only
slightly weaker inhibition of VEGFR2 in comparison to a
VEGFR-selective inhibitor, vatalanib (Table 2).
Another CDK1 inhibitor, JNJ-7706621, was shown to also
inhibit VEGFR2 in vitro [31]. When directly comparing the IC50
values of JNJ-7706621 in a previous study with those of JK-31 in
this study, JNJ-7706621 is more potent than JK-31 in terms of
absolute IC50 values. However, when comparing relative potency,
JNJ-7706621 is a,17-fold more potent inhibitor of CDK1 than
VEGFR2, whereas JK-31 is ,4-fold more selective for VEGFR2
than CDK1. This exemplifies our success in engineering a
compound with true dual targeting characteristics.
JK-31 inhibits VEGF-A-stimulated signal transduction in
primary human endothelial cells
A key feature of VEGFR kinase inhibitors is their ability to
block VEGF-A-stimulated downstream signaling in endothelial
cells [3,6,18,27,34]. Primary human umbilical vein endothelial
cells (HUVECs) recapitulate many features of in vivo vascular
function, including the expression of VEGFR2, Von Willebrand
Factor (VWF) and PECAM-1 (Figure S1). We used immunoblot
analysis of HUVECs treated with VEGF-A and JK-31 to examine
the effects on VEGFR2 autophosphorylation and downstream
signaling to PLCc1, Akt and ERK1/2 (Figures 2A and B). At
concentrations of 10 mM and above, JK-31 caused.60% inhibi-
tion of phosphorylation of residue Y1175 within the VEGFR2
cytoplasmic domain (Figure 2B). JK-31 also inhibited VEGF-A-
stimulated signal transduction in a dose-dependent manner
affecting multiple phosphorylation events such as production of
PLCc1-pY783, Akt-pS473 and ERK1/2-pT202/pY204 epitopes
(Figure 2A). Quantification and statistical analysis clearly showed
a dose-dependent inhibition of VEGF-A-stimulated signal trans-
duction leading to altered phosphorylation status of key enzymes
(Figure S5).
To assess the relative specificity of JK-31 for the VEGF-A-
VEGFR2 pathway, we examined inhibition of signal transduction
through additional growth factor receptor tyrosine kinase axes,
namely acidic FGF (aFGF), basic FGF (bFGF), EGF and IGF-1
(Figures 2C and D; Figure S6A and S6B). JK-31 displayed dose-
dependent inhibition of downstream ERK1/2 phosphorylation in
response to either aFGF or bFGF (Figures 2C and D; Figure S5)
but not in response to either EGF or IGF-1 (Figure S6A and S6B).
Further work to fully characterize the selectivity profile of JK-31
against a wide range of targets using in vitro and cellular assays is
currently ongoing.
can be found in Figure S2. (E–F) JK-31 inhibits the intrinsic kinase activity of both CDK1 and VEGFR2. IC50 curves were generated by incubating
recombinant protein kinases with a peptide substrate, radiolabeled [c-33P]-ATP and either JK-31 or bohemine (5 nM to 100 mM). Effects of JK-31 and
bohemine on phosphate transfer from a (E) recombinant human VEGFR2 to a peptide substrate, poly[Glu:Tyr] (4:1) and (F) recombinant human CDK1/
cyclin B complex to histone H1 substrate in vitro. Line graphs of three independent replicate experiments are shown.
doi:10.1371/journal.pone.0110997.g001
Table 1. Estimated binding affinities (pKi values) of JK-31 to VEGFR2 and CDK1 kinase domains in silico, as predicted using SPROUT
and Glide programs (see Methods).
JK-31
Estimated pKi (SPROUT) Estimated pKi (Glide)
VEGFR2 29.19 29.75
CDK1 28.77 27.13
doi:10.1371/journal.pone.0110997.t001
A Dual Specificity Cell Cycle and Angiogenesis Inhibitor
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JK-31 has in vitro and ex vivo anti-angiogenic activity
Multiple lines of evidence thus far in this study have revealed
JK-31 as an inhibitor of pro-angiogenic receptor tyrosine kinase-
regulated signal transduction in endothelial cells (Table 2;
Figures 1E and 1F; Figure 2). Hence we assessed whether JK-31
could indeed inhibit angiogenesis using both in vitro and ex vivo
models (Figure 3). In an ex vivo assay, mouse aortic ring explants
were seeded onto Matrigel in full growth medium and incubated
with VEGF-A and a dose range of JK-31 for six days (Figure 3A).
At concentrations of 10 mM and above, JK-31 elicited more than
40% inhibition of radial angiogenic sprout formation (Figure 3B).
Table 2. Inhibition of VEGFR2 and CDK1/cyclin B kinase activity by JK-31.
VEGFR2 CDK1/cyclin B
IC50 (mM) +SEM IC50 (mM) +SEM
JK-31 0.627 0.0107 2.54 0.194
Bohemine 0 0 3.89 0.594
Vatalanib 0.32 0.02 - -
Staurosporine 0.00666 - 0.00167 -
IC50 values were derived from curves (Figures 1E and 1F) generated using an in vitro kinase assay (see Methods).
doi:10.1371/journal.pone.0110997.t002
Figure 2. JK-31 inhibits growth factor-stimulated receptor activation and downstream signal transduction. (A) HUVECs were pre-
treated with JK-31 (0, 0.1, 1, 10 or 50 mM) for 30 min followed by 7.5 min stimulation with VEGF-A (25 ng/ml) in the presence of JK-31. Total cell
lysates were prepared and processed for immunoblotting. Levels of phosphorylated VEGFR2, PLCc1, Akt and ERK were analysed using phospho-
specific antibodies. Membranes were stripped and re-probed for total protein levels and a loading control (a-tubulin). (B) Densitometric
quantification of phosphorylated VEGFR2-pY1175 levels in response to VEGF-A and JK-31 treatment. Error bars represent 6 SEM (n= 4; ***p,0.001).
(C-D) JK-31 inhibits FGF-stimulated intracellular signaling in endothelial cells. HUVECs were pre-treated with JK-31 (0, 0.1, 1, 10 or 50 mM) for 30 min
followed by 10 min stimulation with either (C) bFGF (50 ng/ml) or (D) aFGF (50 ng/ml) in the presence of JK-31. Cells were lysed and processed for
immunoblotting. Representative immunoblots of three independent experiments are shown.
doi:10.1371/journal.pone.0110997.g002
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Figure 3. JK-31 inhibits angiogenesis in an ex vivomurine model and in vitro. (A) Effects of JK-31 on ex vivo angiogenic sprouting from wild-
type mouse aortic ring explants. Aortic rings were seeded onto Matrigel and treated with JK-31 (0, 1, 10 or 50 mM) for six days and imaged by phase-
contrast microscopy. Freehand black lines delineate the outermost extent of sprouting. (B) Absolute quantification of angiogenic sprout length. For
each aortic ring, the mean of three longest sprouts was calculated. Error bars represent6SEM (n = 18; ***p,0.001). (C) JK-31 inhibits endothelial tube
formation in vitro in response to exogenous VEGF-A. HUVECs were seeded onto a confluent layer of primary fibroblasts and treated with VEGF-A
(10 ng/ml) for seven days in the presence of DMSO or JK-31 (1, 10 or 50 mM). Co-cultures were stained with CD31 antibody followed by HRP-
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Secondly, an organotypic in vitro model of angiogenesis (where
endothelial cells are grown on a confluent layer of fibroblasts) was
used to assess the effects of JK-31 on VEGF-A-stimulated
endothelial tubular morphogenesis (Figure 3C and 3D). De novo
tubule formation and branching were examined both by
conventional light microscopy (Figure 3C) and by high-resolution
deconvolution microscopy (Figure 3D) using immunolabeling of
the endothelial-specific protein CD31 (PECAM-1). JK-31 dose-
dependently inhibited VEGF-A-stimulated endothelial tube for-
mation (Figures 3C and 3D): approximately 35% inhibition was
observed at 10 mM and more than 80% inhibition at 50 mM
(Figure 3F).
Interestingly however, at 10 mM concentration of JK-31 and in
the presence of VEGF-A, an aberrant hyper-branched endothelial
tubule phenotype was observed with multiple vestigial lamellipo-
dia-like structures emanating from the plasma membrane
(Figure 3D, white arrowheads). This led to a higher branch count
than predicted, despite reduced total CD31-positive staining
(Figures 3F and 3G). At the highest concentration used (50 mM),
more than 80% reduction in branching was observed (Figure 3G).
Inhibition of bFGF-stimulated endothelial tube formation by JK-
31 was more pronounced than for VEGF-A: ,75% inhibition was
observed at 10 mM and more than 95% inhibition at 50 mM
(Figure 3E). In addition, bFGF-stimulated branching was more
severely affected with more than 90% reduction at both 10 mM
and 50 mM JK-31 (Figure 3G).
JK-31 compromises endothelial wound healing in vitro
Endothelial cells in culture form a confluent cell monolayer
[16]. A simple in vitro assay can be used to disrupt this cell
monolayer, for example by a mechanical scratch wound, and the
migration and proliferation of endothelial cells into the denuded
region can be monitored over time. This model thus recapitulates
early events during angiogenesis [6,35]. We assessed the effects of
JK-31 on endothelial cell monolayer wound closure during growth
either in full growth medium or minimal medium supplemented
with VEGF-A alone (Figure 4). At 10 mM concentration and
above, JK-31 completely inhibited VEGF-A-stimulated wound
closure (Figure 4A, 4B) and only partially inhibited wound closure
in full growth medium (Figure 4A).
JK-31 inhibition of human cell proliferation
JK-31 inhibits both a key pro-angiogenic receptor tyrosine
kinase, VEGFR2, and a well-described regulator of the cell cycle,
CDK1. Are such effects evident in different cellular responses
involving VEGFR2 and/or CDK1 that could contribute to
growth of a neovascularized tumor? To address such a scenario,
we first examined the effects of JK-31 on the proliferation of
primary endothelial cells (Figure 5A) and the human breast cancer
cell line MCF-7 (Figure 5B). Immunoblot analysis showed that
both cell types express CDK1 but only endothelial cells express
VEGFR2 (Figure S7A). Using a bromodeoxyuridine (BrdU)
incorporation assay to monitor new DNA synthesis, we found
that JK-31 inhibited proliferation of both human cell types, albeit
at a higher dose range in MCF-7 breast epithelial cells (Figure 5B).
A control CDK1-selective inhibitor, bohemine, showed pro-
nounced inhibition of proliferation of both cell types; however,
the VEGFR-specific inhibitor vatalanib did not significantly
inhibit cell proliferation in endothelial cells (Figure 5A) or breast
cancer cells (Figure 5B). A cell viability assay showed that JK-31
had no significant cytotoxic effects on endothelial cells when
treated for two days at concentrations of up to 50 mM (Figure
S7B).
Effects of JK-31 on the cell cycle in both endothelial cells
and breast cancer cells
VEGFR-selective inhibitors have minimal effects on endothelial
cell cycle progression [18,27,34] whereas CDK-specific inhibitors
conjugated secondary antibody and visualized by light microscopy using 1,1-diaminobenzidine (DAB)-staining (see Materials and Methods). (D)
Fluorescence microscopy analysis of endothelial cell phenotypes and filopodia formation during tubulogenesis in the presence of VEGF-A and JK-31.
White arrowheads indicate vestigial lamellipodia-like structures. (E) JK-31 inhibits endothelial tube formation in vitro in response to exogenous bFGF
(20 ng/ml). Treatment and processing was carried out as described above. Quantification of (F) mean tubule branch length and (G) mean number of
tubule branch points in response to JK-31 and exogenous growth factors. Light micrograph fields were chosen at random and quantification
performed using Image J software. Error bars represent 6 SEM (n = 10; *p,0.05; **p,0.01; ***p,0.001) for each respective growth factor.
doi:10.1371/journal.pone.0110997.g003
Figure 4. JK-31 inhibits endothelial wound closure in vitro. (A)
Scratch-wounded endothelial cell monolayers were incubated in either
full growth medium (grey bars) or stimulated with 25 ng/ml VEGF-A
(black bars) for 16 h in the presence of DMSO or JK-31 (1, 10 or 50 mM).
Wounded cell monolayers were photographed before and after
treatment and wound widths at each time point were measured using
Image J software. Percentage wound closure was calculated by [(width
before – width after)/width before]6100. Error bars represent 6 SEM
(n= 3; *p,0.05; **p,0.01) for each condition. (B) Representative phase-
contrast micrographs depicting wound closure over 16 h in the
presence VEGF-A and either DMSO or JK-31 (10 mM).
doi:10.1371/journal.pone.0110997.g004
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can cause a cell cycle-specific arrest [31,36]. Can JK-31 perturb
cell cycle progression in both endothelial and non-endothelial
cells? To assess this, we compared the expression and phosphor-
ylation status of cyclins and cyclin-dependent kinases (CDKs) in
endothelial cells and MCF-7 breast cancer epithelial cells treated
with either JK-31, nocodazole (a cell synchronization agent),
bohemine (a control CDK1 inhibitor) or sunitinib (a control
VEGFR inhibitor) (Figure 5C and 5D). CDK1 is maintained in an
inhibitory state by phosphorylation at residue Y15, which during
transition from G2 to M phase is rapidly dephosphorylated to
allow for entry into mitosis [31,37]. The cell synchronization agent
nocodazole disrupts microtubule polymerization, arresting cells at
the G2/M phase boundary and leading to loss of CDK1 Y15
phosphorylation (Figure 5C and 5D; Figures S8A and S9A) [31].
In comparison to an asynchronous cell population, nocodazole
also decreased levels of total CDK1, cyclin A and cyclin B, but
increased cyclin D1 levels, consistent with cell cycle arrest at the
G2/M phase boundary (Figure 5C and 5D).
Here, both JK-31 and bohemine partially mimicked the effects
of nocodazole. Whereas bohemine reduced both phospho- and
total CDK1 levels in both endothelial and MCF-7 cells, the effects
on cyclin A and cyclin B were less pronounced (Figure 5C and 5D;
Figure S8B–S8E and S9B–S9D). In endothelial cells, JK-31
showed similar effects to nocodazole at concentrations of 10 mM
and above (Figure 5C; Figure S8A–S8E), whereas in MCF-7 cells,
a higher JK-31 concentration was needed to elicit the same
response (Figure 5D; Figure S9A-S9D), concordant with results
from cell proliferation assays (Figure 5A and 5B). Sunitinib
Figure 5. Effects of JK-31 on proliferation and cell cycle status of primary human endothelial cells and human breast cancer cells. (A)
HUVECs and (B) MCF-7 cells were treated with DMSO, JK-31 (0.1, 1, 10, 50 mM), vatalanib (10 mM) or bohemine (10 mM) in full growth medium for 16 h
followed by labeling with bromodeoxyuridine (BrdU; 10 mM) for 2 h and subsequent ELISA. Absorbance readings at OD450 were normalized and
expressed relative to DMSO control. Error bars represent 6 SEM (n= 4; ***p,0.001). (C) HUVECs and (D) MCF-7 cells were treated with nocodazole
(200 nM), bohemine (10 mM), sunitinib (100 nM) or JK-31 (0, 0.1, 1, 10, 50 mM) for 48 h. Total cell lysates were prepared and immunoblotting carried
out as described in Experimental Section. Membranes were probed for phosphorylated and total CDK1 in addition to cyclin A, B and D1 and a loading
control (a-tubulin). Representative immunoblots of three independent experiments shown.
doi:10.1371/journal.pone.0110997.g005
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exhibited no marked effects on cell cycle protein expression or
phosphorylation when compared to an asynchronous control
(Figures 5C and 5D; Figure S8A–S8E and S9A–S9D). Taken
together, these results suggest that JK-31 causes cell cycle arrest
through inhibition of CDK1 activity (Figure 5C and 5D; Figure
S8A–S8E and S9A–S9D).
To investigate this further, human endothelial or breast cancer
cells were treated with nocodazole, JK-31, sunitinib or bohemine
for 48 h prior to fixation and analysis of cellular DNA status using
flow cytometry. Cells containing n= 1 and n= 2 amount of
genomic DNA were quantified (Figure 6A–7H; 7A–7H and
Figure S10A–S10B), revealing that there was a significant decrease
in the proportion of cells in the G2/M phase of the cell cycle in
both endothelial and breast cancer cells treated with JK-31 at 10
or 50 mM, in comparison to asynchronous controls (Figure 6H
and 7H). This correlated with a significant increase in the number
of cells present in G1 (Figure 6H and 7H). Interestingly, there was
not a significant change in the number of endothelial cells present
in S phase upon JK-31 treatment (Figure 6H). Contrastingly, upon
JK-31 treatment the number of breast cancer cells present in the S
phase of the cell cycle was significantly decreased (Figure 7H).
Treatment with nocodazole arrested both endothelial and human
breast cancer cells at the G2/M phase boundary, promoting a
significant shift in the cell cycle profile (Figure 6H and 7H and
Figure S10A–S10B). However, sunitinib treatment had no effect
on cell cycle progression vs. asynchronous controls in both cell
types (Figure 6H and 7H). Upon treatment with the CDK1
inhibitor bohemine, there was a trend towards an increase in the
number of endothelial and breast cancer cells present in both the S
and G2/M phases of the cell cycle (Figure 6H and 7H).
Interestingly, this suggested that JK-31 and bohemine inhibition
of CDK1 have opposing effects on the cell cycle.
Discussion
The clinical success of promiscuous kinase inhibitors has
stimulated interest in ‘targeted polypharmacology’ i.e. the rational
design of molecules that inhibit an opportune combination of
kinases with optimal selectivity profiles [13–15,38,39]. There have
been numerous recent examples of such ‘selectively non-selective’
kinase inhibitors. Inhibitors of multiple receptor tyrosine kinases
(RTKs) (e.g. brivanib, a dual inhibitor of VEGFR and FGFR
kinases) have proven effective in combating redundancy in
signaling pathways [40,41]. Type II inhibitors of Raf and
platelet-derived growth factor receptor b (PDGFR-b) prevent
angiogenesis by targeting endothelial cells, vascular smooth muscle
cells and pericytes simultaneously [38]. When targeting tumor
progression, inhibition of both lipid and protein tyrosine kinases
has shown promise [14]; similarly, dual inhibition of the Aurora A
and CDK1 kinases targets multiple critical stages in the cell cycle
[31].
Our aim was to design a compound which inhibits two
pathways involved in tumor growth. The combination of
computer-aided molecular modeling strategies and kinase activity
screening enabled the rapid design, pruning and validation of
synthetic aminotriazole compounds, leading to the identification of
JK-31, a molecule that potently inhibits both VEGFR2 and
CDK1. We targeted VEGFR2 because this receptor tyrosine
kinase is a known master regulator of the pro-angiogenic response
[6,42,43]. We targeted the serine/threonine protein kinase CDK1
because it is a critical regulator of entry into mitosis, whose
aberrant expression and control is exhibited in a wide range of
tumors [8,36,37].
Our in silico model identified JK-31 to be an extremely
potent inhibitor of both VEGFR2 and CDK1, displaying a
predicted inhibition of both kinases in the mid- to low
nanomolar range. This trend in potency was translated into
an in vitro kinase assay, in keeping with our prediction that JK-
31 is a more potent inhibitor of VEGFR2 than CDK1. In a
cellular assay (examining effects on VEGF-A-stimulated
VEGFR2 activation and downstream signaling in endothelial
cells), the IC50 of JK-31 was approximately 10-fold higher than
that observed in a cell-free phosphorylation assay using
recombinant protein kinases. One possibility is that recombi-
nant enzymes in a cell-free system are not subject to the same
conformational inactivation as for the native cell-associated
enzyme [38]. In contrast, many anti-angiogenic compounds
display increased potency in a cellular assay than in a cell-free
system relying on purified components [18,34]. The in vitro
potency of JK-31 is within a comparable range to an existing
inhibitor, vatalanib, although the in vivo efficacy of JK-31
remains to be determined. However, the major advantage of
JK-31 over existing anti-angiogenic therapies is a marked anti-
proliferative effect, attributable to the CDK1-inhibiting prop-
erties of this compound [9,18,34]. We can clearly show that JK-
31 has cytostatic effects on both human endothelial and breast
cancer epithelial cells. In addition, JK-31 displays effects on the
cell cycle consistent with arrest at the G1/S phase boundary,
this effect is dissimilar to those observed with nocodazole (an
inhibitor of microtubule polymerization and anti-neoplastic
agent) and surprisingly, bohemine (a commercial CDK1
inhibitor). However CDK1 is known to regulate G1/S and
G2/M phase transition [44,45]. Thus, this phenomenon could
be attributed to the slight differences in various cyclin
expression levels between the two compounds. Whilst these
effects on proliferation and the cell cycle are clear, the
compound does not exhibit non-specific cellular cytotoxicity in
vitro at the concentrations studied here. However, this does not
rule out any serious side effects which could occur from using
the inhibitor in vivo.
A previous study identified synthetic molecules which satisfy the
structural constraints of both pro-angiogenic receptor tyrosine
kinases and cyclin-dependent kinases; however, whilst some
inhibition of cancer cell proliferation was evident, effects on
angiogenesis were not shown [46]. The overall effect of JK-31 on
breast cancer epithelial cells (which lack VEGFR2) was a
reduction in cell proliferation. Moreover, combined inhibition of
CDK1 and VEGFR2 in endothelial cells led to an overall anti-
angiogenic effect: JK-31 inhibited activation of VEGFR2 and its
downstream signaling pathways in VEGF-A-treated endothelial
cells and simultaneously blocked cell proliferation. JK-31 also
showed pronounced inhibition of FGF-stimulated signaling
pathways, another common feature of many anti-angiogenic
compounds [18]. We propose that inhibition of FGF-related
Figure 6. JK-31 inhibits cell cycle progression in endothelial cells. Endothelial cells were cultured in ECGM and treated with either (A) DMSO
(ASYNCHR), (B) 200 nM nocodazole, (C) 1 mM JK-31, (D) 10 mM JK-31, (E) 50 mM JK-31, (F) 100 nM sunitinib or (G) 10 mM bohemine for 48 h, prior to
staining with propidium iodide and assessment of DNA content using flow cytometry. (H) Quantification of cell cycle ratios after inhibitor treatment.
Error bars represent 6SEM (n= 3). ***p,0.001; ****p,0.0001.
doi:10.1371/journal.pone.0110997.g006
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pathways would be beneficial to overcome redundancy observed
with more specific kinase inhibitors [40,41,47]. Moreover JK-31
does not display inhibition of either EGF- or IGF-1-stimulated
signaling pathways, demonstrating the relative specificity of this
compound. Potent inhibition of receptor tyrosine kinase activity
and growth factor-mediated signaling translates to equally potent
inhibition of VEGF-A- and bFGF-stimulated endothelial tube
formation in vitro and angiogenic sprout formation in an ex vivo
murine aortic ring model. In addition, JK-31 potently inhibits
wound closure in an in vitro model.
Conclusion
In summary, we report the development of JK-31, an inhibitor
directed against two structurally dissimilar protein kinases: the
VEGFR2 receptor tyrosine kinase and the CDK1 serine/
threonine protein kinase. The current study argues that a
rationally designed inhibitor based on comprehensive structure-
function analyses can produce a synergistic effect which not only
targets new blood vessel formation and development, but also cell
cycle progression. These findings further realize the potential to
disrupt both tumor angiogenesis and tumor growth with one
compound. Current challenges to anti-angiogenic and anti-cancer
therapy include the targeting of pathways that control refracto-
riness and multidrug resistance (e.g. by inhibitor-mediated
upregulation of ABC transporters), identification of biomarkers
to predict response to therapy and elucidation of inhibitors which
not only retard tumor growth but also cause tumor regression [48–
51]. Although further work is needed to fully characterize the
selectivity profile of JK-31, our study serves as a benchmark for the
development and refinement of similar multi-kinase inhibitors,
enabling modulation of multiple cellular outputs associated with
specific disease states.
Supporting Information
Figure S1 Validation of primary endothelial cells. (A)
Confluent HUVEC monolayers (grown as described in Materials
and Methods) were visualized using phase contrast microscopy.
4X magnification; bar, 1000 mm. For immunofluorescence
microscopy, confluent HUVECs were labeled with (B) anti-Von
Willebrand Factor (VWF), (C) anti-VEGFR1, (D) anti-VEGFR2
and (E) anti-PECAM-1 (CD31) primary antibodies followed by
secondary anti-species antibodies conjugated to AlexaFluor488
(green) and visualized using fluorescence miscroscopy. Nuclei were
labeled with a DNA stain, DAPI (blue). Bar, 200 mm.
(TIF)
Figure S2 Homology modeling of CDK1 and sequence
alignments. (A) Structural representation of sequence-aligned
CDK1 and VEGFR2 kinase domains with inset showing the ATP-
binding pocket. VEGFR2 crystal structure is shown in yellow.
CDK1 crystal structure is shown in blue/grey. (B) Sequence
alignment of CDK1 and CDK2 proteins used to create a
homology model in Figure 1. Further information on the
homology model and docking studies can be found in Materials
and Methods.
(TIF)
Figure S3 Validation of a CDK1 homology model.
Chemical moieties predicted to interact with residues of the
CDK1 ATP-binding domain hinge region are shown in blue. (A)
Chemical structure of JK-31 showing moieties predicted to
interact with CDK1. (B) Chemical structure of the previously
characterized CDK1 inhibitor AT7519, showing moieties pre-
dicted to interact with CDK1. (C) JK-31 and AT7519 were
docked into the CDK1 homology model simultaneously using the
program Glide to create a docking overlay. Both compounds were
predicted to make hydrogen bond contacts with residues E81 and
L83 of the homology model. (D) Chemical structure of the
diaminothiazole inhibitor previously described [30] showing
moieties predicted to interact with CDK1. (E) JK-31 and the
diaminothiazole inhibtor were docked into the CDK1 homology
model simultaneously using the program Glide to create a docking
overlay. Both compounds were predicted to make hydrogen bond
contacts with residues E81 and L83 of the homology model.
Magenta structure = JK-31; yellow structure = AT7519; cyan
structure = diaminothiazole inhibitor; green structure = residues
of CDK1 kinase domain.
(TIF)
Figure S4 Docking overlay of JK-31 and previously
characterized VEGFR2 inhibitors. Chemical moieties pre-
dicted to interact with residues of the VEGFR2 ATP-binding
domain hinge region are shown in blue. (A) Chemical structure of
PD173074 (a dual VEGFR/FGFR inhibtor) showing moieties
predicted to interact with VEGFR2. (B) JK-31 and PD173074
were docked into the VEGFR2 kinase domain simultaneoulsy
using the program Glide to create a docking overlay. Both
compounds were predicted to make hydrogen bond contacts with
residues E917 and C919 of VEGFR2. (C) Chemical structure of a
derivative of the VEGFR2 inhibitor pazopanib showing moieties
predicted to interact with VEGFR2. (D) JK-31 and the pazopanib
derivative were docked into the VEGFR2 kinase domain
simultaneously using the program Glide to create a docking
overlay. Both compounds were predicted to make hydrogen bond
contacts with residues E917 and C919 of VEGFR2. (E) Chemical
structure of a derivative of the VEGFR2 inhibitor JK-P3 showing
moieties predicted to interact with VEGFR2. (F) JK-31 and JK-P3
were docked into the VEGFR2 kinase domain simultaneously
using the program Glide to create a docking overlay. Both
compounds were predicted to make hydrogen bond contacts with
residues E917 and C919 of VEGFR2. Magenta structure = JK-
31; yellow structure = PD173074; cyan structure = pazopanib
derivative; pink structure = JK-P3; green structure = residues of
VEGFR2 kinase domain.
(TIF)
Figure S5 Quantification of JK-31 inhibition on growth
factor-stimulated endothelial cell signal transduction.
Quantification and statistical analysis of JK-31 treatment on (A)
PLCc1-pY783, (B) Akt-pS473 and (C-E) ERK1/2-pT202/Y204
levels in response to (A-C) VEGF-A, (D) aFGF or (E) bFGF
stimulation of endothelial cells. Error bars represent 6SEM
(n= 3). *p,0.05; **p,0.01; ***p,0.001.
(TIF)
Figure S6 Relative specificity of JK-31 for the VEGF-A-
VEGFR2 signaling pathway. JK-31 does not inhibit (A) EGF-
Figure 7. JK-31 inhibits cell cycle progression in human breast cancer cells. Human breast cancer cells were treated with either (A) DMSO
(ASYNCHR), (B) 200 nM nocodazole, (C) 1 mM JK-31, (D) 10 mM JK-31, (E) 50 mM JK-31, (F) 100 nM sunitinib or (G) 10 mM bohemine for 48 h, prior to
staining with propidium iodide and assessment of DNA content using flow cytometry. (H) Quantification of cell cycle ratios after inhibitor treatment.
Error bars represent 6SEM (n= 3).). *p,0.05; **p,0.01; ***p,0.001; ****p,0.0001.
doi:10.1371/journal.pone.0110997.g007
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or (B) IGF-1-mediated signaling in endothelial cells. HUVECs
were pre-treated with JK-31 (0, 0.1, 1, 10 or 50 mM) for 30 min
followed by a 10 min stimulation with either (A) EGF (50 ng/ml)
or (B) IGF-1 (100 ng/ml) in the presence of JK-31. Total cell
lysates were prepared and processed for immunoblotting. Levels of
phosphorylated Akt and ERK1/2 were analysed using phospho-
specific antibodies. Membranes were stripped and re-probed for
total protein levels and a loading control (a-tubulin). Represen-
tative immunoblots of three independent experiments are shown.
(TIF)
Figure S7 JK-31 does not compromise endothelial cell
viability. (A) Relevant protein expression in HUVECs and
MCF-7 cells. Total cell lysates were processed for immunoblotting.
Membranes were probed with antibodies raised against VEGFR2,
CDK1 and b-actin. Representative immunoblot was shown. (B)
HUVECs were treated with DMSO or JK-31 (0.1, 1, 10, 50 mM)
in full growth medium for 48 h followed by MTS assay and
subsequent measurement of absorbance at OD490. Error bars
represent 6SEM (n= 5).
(TIF)
Figure S8 Quantification of the effects of JK-31 on cell
cycle status in endothelial cells. Quantification and statistical
analysis of (A) phospho-CDK1, (B) CDK1, (C) Cyclin B, (D),
Cyclin A and (E) Cyclin D1 levels in endothelial cells treated with
nocodazole, bohemine, sutinib and JK-31 for 48 h. Statistics
presented relative to ansyncronous controls. Error bars represent
6SEM (n= 3). *p,0.05; **p,0.01; ***p,0.001.
(TIF)
Figure S9 Quantification of the effects of JK-31 on cell
cycle status in human breast cancer cells. Quantification
and statistical analysis of (A) phospho-CDK1, (B) CDK1, (C)
Cyclin B and (D), Cyclin A levels in human breast cancer cells
treated with nocodazole, bohemine, sutinib and JK-31 for 48 h.
Statistics presented relative to ansynchronous conrtrols. Error bars
represent 6SEM (n=3). *p,0.05; **p,0.01; ***p,0.001.
(TIF)
Figure S10 Quantification of the effects of nocodazole
treatment on cell cycle progression in endothelial and
human breast cancer cells. Quantification and statistical
analysis of cell cycle progression in (A) endothelial (HUVEC) or (B)
epithelial (MCF-7) cells upon treatment with 200 nM nocodazole
for 48 h. Statistics presented relative to ansynchronous
(ASYNCHR) controls. Error bars represent 6SEM (n= 3).
***p,0.001; ****p,0.0001.
(TIF)
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